{"id":"consolidation-paclitaxel","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Paclitaxel binds to tubulin, a protein that makes up microtubules, and prevents them from disassembling. This leads to the accumulation of microtubules, which in turn prevents the cell from entering the mitotic phase of cell division. As a result, cancer cells are unable to multiply and the tumor grows more slowly.","oneSentence":"Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:28:21.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT03141359","phase":"PHASE2","title":"Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-12","conditions":"Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT02525757","phase":"PHASE2","title":"MPDL3280A With Chemoradiation for Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-26","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT07103395","phase":"PHASE2","title":"A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT07340489","phase":"PHASE2","title":"Serplulimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-03","conditions":"Cervical Cancer","enrollment":216},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT06139419","phase":"PHASE2","title":"The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-25","conditions":"Non-small Cell Lung Cancer","enrollment":114},{"nctId":"NCT03916419","phase":"PHASE2","title":"Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-06-20","conditions":"Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":26},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT01270724","phase":"PHASE2","title":"Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-08","conditions":"CNS Germ Cell Tumor","enrollment":10},{"nctId":"NCT02186847","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2014-08","conditions":"Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma","enrollment":170},{"nctId":"NCT06420908","phase":"NA","title":"Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"WITHDRAWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-05-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07086456","phase":"PHASE2","title":"Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy","enrollment":80},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT07052669","phase":"PHASE3","title":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-01","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":311},{"nctId":"NCT04046575","phase":"PHASE1","title":"Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-11-07","conditions":"Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus","enrollment":12},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT04585490","phase":"PHASE3","title":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","status":"RECRUITING","sponsor":"Maximilian Diehn","startDate":"2021-08-25","conditions":"Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc","enrollment":48},{"nctId":"NCT06916117","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-05","conditions":"Locally Advanced Cervical Cancer","enrollment":30},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04943445","phase":"PHASE2","title":"Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2022-02-22","conditions":"Squamous Cell Carcinoma of Larynx","enrollment":43},{"nctId":"NCT01993810","phase":"PHASE3","title":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2014-02-03","conditions":"Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","enrollment":330},{"nctId":"NCT05919030","phase":"PHASE3","title":"A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Renmin Hospital of Wuhan University","startDate":"2023-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":155},{"nctId":"NCT02492867","phase":"NA","title":"A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-01-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT06468644","phase":"PHASE2","title":"Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-06-17","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06401447","phase":"NA","title":"TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT02567799","phase":"PHASE1, PHASE2","title":"BIO 300 Non-Small Cell Lung Cancer Study","status":"COMPLETED","sponsor":"Humanetics Corporation","startDate":"2015-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":21},{"nctId":"NCT02073968","phase":"PHASE2","title":"PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-07","conditions":"Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT04992780","phase":"PHASE2","title":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-25","conditions":"Non Small Cell Lung Cancer Stage","enrollment":50},{"nctId":"NCT05994339","phase":"PHASE2, PHASE3","title":"Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer","status":"UNKNOWN","sponsor":"Laibin People's Hospital","startDate":"2023-09-01","conditions":"Lung Cancer Stage III","enrollment":40},{"nctId":"NCT00828009","phase":"PHASE2","title":"BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-01-17","conditions":"Lung Cancer","enrollment":70},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT03102242","phase":"PHASE2","title":"Atezolizumab Immunotherapy in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-11-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":64},{"nctId":"NCT01912625","phase":"PHASE1","title":"Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-28","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":16},{"nctId":"NCT05547828","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2022-12-20","conditions":"ESCC","enrollment":20},{"nctId":"NCT02394535","phase":"PHASE1","title":"Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-12","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":25},{"nctId":"NCT05455918","phase":"PHASE2","title":"Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2020-07-26","conditions":"Pediatric Germ Cell Tumor","enrollment":42},{"nctId":"NCT00533949","phase":"PHASE3","title":"High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2007-11","conditions":"Lung Cancer, Radiation Toxicity","enrollment":544},{"nctId":"NCT00979212","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-02","conditions":"Lung Cancer","enrollment":71},{"nctId":"NCT02684461","phase":"PHASE2","title":"Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-09-13","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT01757288","phase":"PHASE1, PHASE2","title":"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-03-25","conditions":"STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER","enrollment":98},{"nctId":"NCT04982549","phase":"PHASE2","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-01-21","conditions":"Unresectable Stage III NSCLC","enrollment":35},{"nctId":"NCT04084158","phase":"PHASE2","title":"A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.","status":"SUSPENDED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-09-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT03699033","phase":"PHASE2","title":"Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Stephanie Smiddy","startDate":"2018-10-01","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03945227","phase":"PHASE2","title":"Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2019-06","conditions":"Stage III NSCLC","enrollment":""},{"nctId":"NCT02412371","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-04-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":48},{"nctId":"NCT04453904","phase":"NA","title":"Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2020-05-12","conditions":"Endometrial Cancer","enrollment":654},{"nctId":"NCT04203511","phase":"PHASE3","title":"INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2020-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04261465","phase":"PHASE2","title":"NUVOLA TRIAL Open-label Multicentre Study","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-12-01","conditions":"High Grade Serous Ovarian Cancer","enrollment":35},{"nctId":"NCT00003402","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1999-01","conditions":"Leukemia, Lymphoma","enrollment":35},{"nctId":"NCT00003399","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1998-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00003401","phase":"PHASE2","title":"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1999-01","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00096226","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-09","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT01196429","phase":"PHASE2","title":"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08","conditions":"Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":90},{"nctId":"NCT01822496","phase":"PHASE2","title":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-04","conditions":"Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7","enrollment":59},{"nctId":"NCT00547443","phase":"PHASE1, PHASE2","title":"Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT03328234","phase":"PHASE3","title":"Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2017-09-01","conditions":"IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer","enrollment":2},{"nctId":"NCT03308552","phase":"PHASE3","title":"Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2017-12-01","conditions":"Esophageal Neoplasms","enrollment":164},{"nctId":"NCT00520013","phase":"PHASE2","title":"Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":60},{"nctId":"NCT01921751","phase":"PHASE2","title":"High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-08","conditions":"Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer","enrollment":20},{"nctId":"NCT00055601","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-12","conditions":"Bladder Cancer","enrollment":97},{"nctId":"NCT00738452","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-08-06","conditions":"Lung Cancer","enrollment":10},{"nctId":"NCT01486602","phase":"PHASE1","title":"Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-03","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT02172846","phase":"PHASE1","title":"Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":23},{"nctId":"NCT00511992","phase":"PHASE2","title":"Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2007-07","conditions":"Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma","enrollment":20},{"nctId":"NCT00094861","phase":"PHASE2","title":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer","enrollment":100},{"nctId":"NCT00492206","phase":"PHASE2","title":"Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-06","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":40},{"nctId":"NCT00314678","phase":"PHASE2","title":"Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"John P. Fruehauf","startDate":"2005-09","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Cancer","enrollment":40},{"nctId":"NCT00003899","phase":"PHASE1","title":"Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-01","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01488552","phase":"PHASE1, PHASE2","title":"Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Research Team","startDate":"2011-11","conditions":"Stage IV Pancreatic Cancer","enrollment":60},{"nctId":"NCT00003812","phase":"PHASE2","title":"Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-03","conditions":"Lung Cancer","enrollment":75},{"nctId":"NCT00033696","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Lung Cancer","enrollment":65},{"nctId":"NCT00686959","phase":"PHASE3","title":"Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Non Small Cell Lung Cancer","enrollment":598},{"nctId":"NCT00129727","phase":"PHASE2","title":"Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-06","conditions":"Ovarian Cancer","enrollment":62},{"nctId":"NCT01755845","phase":"PHASE3","title":"Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients","status":"UNKNOWN","sponsor":"xie congying","startDate":"2011-01","conditions":"Cervical Cancer","enrollment":300},{"nctId":"NCT00216125","phase":"PHASE3","title":"Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Nasser Hanna, M.D.","startDate":"2002-02","conditions":"Non-Small Cell Lung Cancer","enrollment":243},{"nctId":"NCT00198432","phase":"PHASE2","title":"Chemoradiotherapy of NSCLC Stage IIIB","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2002-03","conditions":"NSCLC Stage IIIB, Concomitant Radiochemotherapy","enrollment":130},{"nctId":"NCT01393080","phase":"NA","title":"Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2011-03","conditions":"Non-small Cell Lung Cancer","enrollment":160},{"nctId":"NCT01494415","phase":"PHASE2","title":"Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2012-07","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell","enrollment":21},{"nctId":"NCT02430974","phase":"PHASE2","title":"Chemotherapy of NSCLC With or Without Icotinib","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":50},{"nctId":"NCT00550784","phase":"PHASE1","title":"Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2001-01","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":8},{"nctId":"NCT00369551","phase":"PHASE1","title":"Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":36},{"nctId":"NCT00017303","phase":"PHASE2","title":"Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Cytran","startDate":"2001-01","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00042835","phase":"PHASE1","title":"Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-05","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Consolidation Paclitaxel","genericName":"Consolidation Paclitaxel","companyName":"Radiation Therapy Oncology Group","companyId":"radiation-therapy-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}